NewAmsterdam Pharma enters merger deal with Frazier Lifesciences
Pharmaceutical Technology
JULY 26, 2022
NewAmsterdam Pharma has signed a definitive business combination agreement with special purpose acquisition company (SPAC) Frazier Lifesciences Acquisition (FLAC). This pro forma cash balance of nearly $470m is anticipated to offer a cash runway for the merged company through 2026.
Let's personalize your content